Literature DB >> 6304440

Conformationally constrained cyclic enkephalin analogs with pronounced delta opioid receptor agonist selectivity.

H I Mosberg, R Hurst, V J Hruby, J J Galligan, T F Burks, K Gee, H I Yamamura.   

Abstract

The enkephalin analogs, [D-Pen2,L-Cys5]- and [D-Pen2,D-Cys5]-enkephalin are cyclic compounds, conformationally constrained by virtue of their 14-membered, disulfide containing rings and by the rigidizing effect of the beta, beta dimethyl substituents of the penicillamine side chain. The analogs exhibit profound delta receptor specificity as assessed by their relative potencies in the guinea pig ileum (GPI) and mouse vas deferens (MVD) assays, exhibiting, respectively, 666 and 215 times higher potency in the latter assay system. By contrast, the receptor selectivities measured in rat brain binding assays in the absence of sodium were much more modest, the cyclic analogs being, respectively, 15.2 and 6.0 times more effective at displacing [3H] [D-Ala2,D-Leu5]enkephalin than [3H]naloxone. However, for binding assays performed in the presence of a sodium concentration equivalent to that used in the GPI and MVD assays, these binding selectivities increased to 167 and 49, respectively.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304440     DOI: 10.1016/0024-3205(83)90239-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  A proposal for the molecular basis of mu and delta opiate receptor differentiation based on modeling of two types of cyclic enkephalins and a narcotic alkaloid.

Authors:  A Michel; G Villeneuve; J DiMaio
Journal:  J Comput Aided Mol Des       Date:  1991-12       Impact factor: 3.686

3.  Characterization of [3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin binding to delta opiate receptors in the rat brain and neuroblastoma--glioma hybrid cell line (NG 108-15).

Authors:  K Akiyama; K W Gee; H I Mosberg; V J Hruby; H I Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

4.  Characterization of cyclic peptides containing disulfide bonds.

Authors:  Mindy Johnson; Mingtao Liu; Elaine Struble; Kanthi Hettiarachchi
Journal:  J Pharm Biomed Anal       Date:  2015-01-22       Impact factor: 3.935

Review 5.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

6.  Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.

Authors:  Richard S Agnes; Jinfa Ying; Katalin E Kövér; Yeon Sun Lee; Peg Davis; Shou-wu Ma; Hamid Badghisi; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Peptides       Date:  2008-04-10       Impact factor: 3.750

7.  Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors.

Authors:  H I Mosberg; R Hurst; V J Hruby; K Gee; H I Yamamura; J J Galligan; T F Burks
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

8.  Bioactive conformations of two seminal delta opioid receptor penta-peptides inferred from free-energy profiles.

Authors:  Guido Scarabelli; Davide Provasi; Ana Negri; Marta Filizola
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

9.  Central delta-opioid receptor interactions and the inhibition of reflex urinary bladder contractions in the rat.

Authors:  A Dray; L Nunan; W Wire
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

10.  Roles of delta and mu opioid receptors in mediating the effects of enkephalins on avoidance conditioning.

Authors:  G Schulteis; J L Martinez
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.